Marksans Pharma Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/mypuwfmqf493s381tkl1myfv.pdf

Key Takeaways


Revenue Growth & Market Performance

Mark Saldanha: "I do believe our U.K. will grow in terms of revenue and will beat market expectations. The only thing is it will take a bit longer."

Gross Margin & Cost Dynamics

Mark Saldanha: "I think it is sustainable, but buying the geopolitical situation that continues to evolve on a daily basis, we do see freight pricing challenges happening. We are hoping it is not going to be for long, but as of today, freight is again taking up."

Teva Plant Ramp-Up


U.K. Product Pipeline & Margin Accretion

Mark Saldanha: "These are margin-lucrative items. They are very niche products. Difficult molecules. So, they are not value drivers in terms of if you're asking whether the molecules will do a GBP1 crore sales. That may not happen. But the bottom-line improvement, it will add tremendous value to the bottom line."

Strategy & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue targetReach INR3,000 croresWithin the next two years
Teva plant quarterly run-rateHit close to INR100 crores per quarterBy Q3 FY25
Teva plant full-year contributionTrending at INR200 crores for the year, with Q4 better than Q3FY25
New U.K. product launchNiche authorized products to go live after manufacturing, shipping, import, testing, and releaseThree to four months from authorization
Second facility scaleContribute larger than the first facilityMay take this financial year
R&D spending rangeRemain in the same rangeAt least the next two years
Gross margin sustainabilityCurrent level sustainable, subject to freight and geopolitical evolutionOngoing, monitored quarterly

Key Metrics

MetricQ1 FY25
Operating revenue₹590.6 cr, +18.1% YoY
U.S. and North America revenue₹251 cr, +29.8% YoY
U.K. and EU formulation revenue₹251.5 cr, +11.3% YoY
Australia and New Zealand revenue₹65.6 cr, +12% YoY
Rest of the world revenue₹22.7 cr
Gross margin55.7%, +423 bps YoY from 51.5%
EBITDA₹128.4 cr, +26% YoY and +17.1% QoQ
EBITDA margin21.7%
Profit after tax₹89.1 cr, +26.4% YoY
EPS₹2
Cash from operations₹45 cr
Capex₹31 cr
R&D spend₹12 cr, 2% of sales
Total cash₹691 cr as of June 30, 2024, debt-free
Additional freight cost YoY₹12 cr
Teva plant revenue contribution₹60 cr in Q1, ₹30 cr in July
Newly acquired facility capacity utilization~40%
Other facilities capacity utilization~65%
U.S. order book₹18 cr, executable over next two years
Goa facility annual sales₹750 cr to ₹800 cr
Revenue target₹3,000 cr within next two years